HUE030102T2 - Anti-caprin-1 antitesteket tartalmazó gyógyászati készítmény rák kezelésére és/vagy megelõzésére - Google Patents
Anti-caprin-1 antitesteket tartalmazó gyógyászati készítmény rák kezelésére és/vagy megelõzésére Download PDFInfo
- Publication number
- HUE030102T2 HUE030102T2 HUE11739865A HUE11739865A HUE030102T2 HU E030102 T2 HUE030102 T2 HU E030102T2 HU E11739865 A HUE11739865 A HU E11739865A HU E11739865 A HUE11739865 A HU E11739865A HU E030102 T2 HUE030102 T2 HU E030102T2
- Authority
- HU
- Hungary
- Prior art keywords
- gin
- ser
- glu
- pro
- ala
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (8)
- kmmtmm-i ANTITESTEKET tartalmazó GYÖSYÁSZAT! KÉSZÍTMÉNY RAK KEZELÉSÉRE ÉS/VAGY MEGELŐZÉSÉRE SZABADALMI JOÉNYEONTOK1, Antitest vagy annak fragmense, amely képes kötődni CAPRtN-1 egy rész-polipeptidjéhez, atiöl a CAPRIN-1 Jelentés© a SEQ ID NO :2--30 (azaz 2-30 azonosító számú) szekvenöiák közül bármelyik páros azonosító számú által bemutatott, és alól a rész-poiipeptid a SEQ ID NO: 3?-ben bemutatott aminosav-szekvenctából áll, vagy olyan aminosav-szekvenclábói, amely legalább 80%-os SzekvenciaazonossÉgot mutat a SEQ ID NÖ: 37 szerinti aminosav-szekveneíávai,
- 2, Az 1. igénypont szerinti antitest: vagy annak fragmense, amely citotoxikus áPyitást mutat olyan rákos sejttel szemben, amely expresszi! egy CAPRiN-1 fehérjét
- 3, Az 1. vagy 2. igénypont szerinti antitest vagy annak fragmense, amely tartaimaz olpn nehézláno variábilis régiót, amely tartalmazza a SEQ ID NQ: 40, 41 és 42 szerinti szekvenciákat és olyan könnyiláno variábilis régiót, amely tartalmazza a SEQ ID NO: 44: 45 és 46 szerinti szekvenciákat, és képes kötődni egy óAPRIN-1 fehérjéhez, % Az 1 vagy 2. igénypont szerinti antitest vagy annak fragmense., amely tartalmaz olyan nehézláno variábilis régiót, amely tartalmasa a SEQ ID NO: 40, 41 és 42 szerinti szekvenciákat, és olyan könnyülánc variibls régiót, amely tartalmazza a SEQ ID NO: 50, 51 és 52 szerinti szekvenciákat, és képes kötődni egy CAPRIN-1 fehérjéhez.
- 5, Az 1-4. igénypontok bármelyike szerinti antitest vagy annak fragmense, ahol az antitest vagy fragmense monokionáiis. C Az 1. vagy 2. igénypont szerinti antitest vagy annak fragmense, ahol az antitest vagy fragmense políklonália. Ϋ* Az 1 -5. igénypontok bármelyike szerinti antitest vagy annak fragmense; amely humanizált antitest, kimére antitest: egyláncú antitest vagy bispeeifikus antitest & Az 1 vagy 2. igénypont: vagy az 5. igénypont 1 vagy 2. igényponttól függő részé szerinti antitest vagy annak fragmense amely barnán antitest f* gyógyászati kész Ítmény, amely hatóanyagként tartalmaz az előző igénypontok bármelyiké szerinti antitestet vagy annak fragmensét. 18, A 9. igénypont szerinti gyógyászati készítmény, amely lumomllenes ágenst is "tartalmaz.
- 11, Gyógyászati kombináció: amely tartalmazza a 9> igénypont szerinti gyógyászati kéSZítrninyt, valamint tartalmaz tumorellenes ágenst tartalmazó gyógyászati kéezifmeriyt,
- 12, Az 1-8, Igénypontok bármelyike szerinti antitest, a 9. vagy 10, igénypont szerinti gyógyászai készítmény vagy a 11. igénypont szerinti gyógyászati kómbináéló lyóiyszerként történő alkalmazásra.
- 13, Az 1-8. igénypontok bármelyike szerinti antitest, a 0, vagy 10. igénypont szerinti gyógyászai készítmény vagy a 11. igénypont szerinti gyógyászati kombináció rák kezelésére és/vagy megelőzésére szolgáló eljárásban történő alkalmazásra,
- 14, Az antitest, a fragmens vagy a gyógyászati készítmény alkalmazásra a 13. igénypont szerint, ahol az eljárás során beadjuk egy alanynak az 1-8. igénypontok bármelyike szériái antitestet vagy annak fragmensét, vagy a 9: igénypont szerinti gyógyászati készítményt és tumorellenes ágenst. IS. Az antitest, fragmens, gyógyászati készítmény, gyógyászati kombináció· vagy tumorelienes ágens alkalmazásra a 13. vagy 14. igénypont szerint, ahol a rák mellrák, agyrák, leukémia, ümfönia, tüdőrák, masztocitóma, veserák, méhnyakfák.. högyhótyagrék, nyelöcsörák, gyomorrák vagy kolorektális rák.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010023450 | 2010-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030102T2 true HUE030102T2 (hu) | 2017-04-28 |
Family
ID=44355511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11739865A HUE030102T2 (hu) | 2010-02-04 | 2011-02-04 | Anti-caprin-1 antitesteket tartalmazó gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
Country Status (16)
Country | Link |
---|---|
US (1) | US8911740B2 (hu) |
EP (1) | EP2532364B1 (hu) |
JP (1) | JP5923985B2 (hu) |
KR (1) | KR101871704B1 (hu) |
CN (1) | CN102834113B (hu) |
AU (1) | AU2011211682B2 (hu) |
BR (1) | BR112012018948B1 (hu) |
CA (1) | CA2788545C (hu) |
DK (1) | DK2532364T3 (hu) |
ES (1) | ES2583777T3 (hu) |
HU (1) | HUE030102T2 (hu) |
MX (1) | MX340016B (hu) |
PL (1) | PL2532364T3 (hu) |
PT (1) | PT2532364T (hu) |
RU (1) | RU2598258C2 (hu) |
WO (1) | WO2011096517A1 (hu) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101606779B1 (ko) | 2008-08-05 | 2016-03-28 | 도레이 카부시키가이샤 | 암의 검출 방법 |
CN106039307A (zh) | 2008-08-05 | 2016-10-26 | 东丽株式会社 | 用于治疗和预防癌症的药物组合物 |
BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
KR101843807B1 (ko) * | 2010-02-04 | 2018-03-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
CN102822335B (zh) | 2010-02-04 | 2015-09-30 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
HUE030102T2 (hu) | 2010-02-04 | 2017-04-28 | Toray Industries | Anti-caprin-1 antitesteket tartalmazó gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
KR101758117B1 (ko) | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
MX351414B (es) | 2011-08-04 | 2017-10-13 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. |
HUE033628T2 (hu) | 2011-08-04 | 2017-12-28 | Toray Industries | Eljárás hasnyálmirigyrák detektálására |
JP6065592B2 (ja) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
KR101980554B1 (ko) | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
EP2740793B1 (en) | 2011-08-04 | 2017-11-29 | Toray Industries, Inc. | Drug composition for cancer treatment and/or prevention |
DK2740794T3 (en) | 2011-08-04 | 2018-06-14 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION |
WO2013018894A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
EP2818482B1 (en) * | 2012-02-21 | 2019-05-22 | Toray Industries, Inc. | Pharmaceutical composition for treatment of cancer |
PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
MX363136B (es) | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
HUE036424T2 (hu) | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére |
KR102052400B1 (ko) | 2012-03-30 | 2019-12-06 | 도레이 카부시키가이샤 | 담낭암의 치료 및/또는 예방용 의약 조성물 |
CA2879185C (en) | 2012-07-19 | 2021-08-24 | Toray Industries, Inc. | Method for detecting cancer |
WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
CN105452294B (zh) * | 2013-08-09 | 2019-08-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
BR112019008335A2 (pt) | 2016-10-28 | 2020-01-28 | Toray Industries | conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer |
AU2019242520A1 (en) | 2018-03-30 | 2020-10-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
KR20220004634A (ko) | 2019-03-15 | 2022-01-11 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | Her2를 표적으로 하는 면역접합체 |
KR20220153621A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
EP4119156A4 (en) | 2020-03-12 | 2024-05-08 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
US20230165957A1 (en) | 2020-03-12 | 2023-06-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
CA3175129A1 (en) | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
US20230159635A1 (en) | 2020-03-12 | 2023-05-25 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2022270524A1 (hu) | 2021-06-23 | 2022-12-29 | ||
BR112023026985A2 (pt) | 2021-06-23 | 2024-03-12 | Toray Industries | Medicamento para o tratamento e/ou prevenção do câncer, agente que aumenta a eficácia do medicamento em uma composição farmacêutica, agente para aumentar a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer |
EP4378476A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
EP4378477A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
MX2024000965A (es) | 2021-07-27 | 2024-02-09 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
WO2023033129A1 (ja) | 2021-09-03 | 2023-03-09 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
DK1069185T3 (da) | 1998-04-03 | 2011-06-27 | Chugai Pharmaceutical Co Ltd | Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
CA2334038A1 (en) | 1998-07-14 | 2000-01-27 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
AU4185100A (en) * | 1999-04-02 | 2000-10-23 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
JP2003528587A (ja) | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 27個のヒト分泌タンパク質 |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
AU2001261007A1 (en) | 2000-03-29 | 2001-10-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
JP4115281B2 (ja) | 2001-05-11 | 2008-07-09 | キリンファーマ株式会社 | ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物 |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
RU2319709C2 (ru) * | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
EP1629119A2 (en) | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
PL1735348T3 (pl) | 2004-03-19 | 2012-11-30 | Imclone Llc | Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu |
DK1730191T3 (da) | 2004-03-30 | 2011-10-17 | Glaxo Group Ltd | Immunglobulin som binder HOSM |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
JP5006802B2 (ja) | 2005-02-18 | 2012-08-22 | チルドレンズ メディカル センター コーポレイション | 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのCyr61 |
CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
CA2642342A1 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
JP5083091B2 (ja) | 2008-07-24 | 2012-11-28 | 大日本印刷株式会社 | 非接触型データキャリア用導電部材の形成方法及び装置 |
CN106039307A (zh) * | 2008-08-05 | 2016-10-26 | 东丽株式会社 | 用于治疗和预防癌症的药物组合物 |
MX348464B (es) | 2008-08-05 | 2017-06-14 | Toray Industries | Agente inductor de inmunidad. |
KR101606779B1 (ko) * | 2008-08-05 | 2016-03-28 | 도레이 카부시키가이샤 | 암의 검출 방법 |
CN102822335B (zh) | 2010-02-04 | 2015-09-30 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
KR101758117B1 (ko) * | 2010-02-04 | 2017-07-14 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
KR101843807B1 (ko) | 2010-02-04 | 2018-03-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
CN102821788B (zh) | 2010-02-04 | 2016-11-16 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
HUE030102T2 (hu) | 2010-02-04 | 2017-04-28 | Toray Industries | Anti-caprin-1 antitesteket tartalmazó gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
WO2013018894A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
MX351414B (es) | 2011-08-04 | 2017-10-13 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. |
HUE033628T2 (hu) | 2011-08-04 | 2017-12-28 | Toray Industries | Eljárás hasnyálmirigyrák detektálására |
-
2011
- 2011-02-04 HU HUE11739865A patent/HUE030102T2/hu unknown
- 2011-02-04 EP EP11739865.1A patent/EP2532364B1/en active Active
- 2011-02-04 WO PCT/JP2011/052382 patent/WO2011096517A1/ja active Application Filing
- 2011-02-04 BR BR112012018948-4A patent/BR112012018948B1/pt active IP Right Grant
- 2011-02-04 CN CN201180016880.6A patent/CN102834113B/zh active Active
- 2011-02-04 KR KR1020127022729A patent/KR101871704B1/ko active IP Right Grant
- 2011-02-04 CA CA2788545A patent/CA2788545C/en active Active
- 2011-02-04 RU RU2012137499/10A patent/RU2598258C2/ru active
- 2011-02-04 ES ES11739865.1T patent/ES2583777T3/es active Active
- 2011-02-04 DK DK11739865.1T patent/DK2532364T3/en active
- 2011-02-04 PT PT117398651T patent/PT2532364T/pt unknown
- 2011-02-04 JP JP2011510206A patent/JP5923985B2/ja active Active
- 2011-02-04 US US13/577,028 patent/US8911740B2/en active Active
- 2011-02-04 MX MX2012008997A patent/MX340016B/es active IP Right Grant
- 2011-02-04 PL PL11739865.1T patent/PL2532364T3/pl unknown
- 2011-02-04 AU AU2011211682A patent/AU2011211682B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX340016B (es) | 2016-06-22 |
BR112012018948B1 (pt) | 2021-12-14 |
PT2532364T (pt) | 2016-07-28 |
KR20120139719A (ko) | 2012-12-27 |
JPWO2011096517A1 (ja) | 2013-06-13 |
CN102834113B (zh) | 2016-03-02 |
PL2532364T3 (pl) | 2016-11-30 |
AU2011211682B2 (en) | 2015-08-13 |
CA2788545A1 (en) | 2011-08-11 |
WO2011096517A1 (ja) | 2011-08-11 |
RU2012137499A (ru) | 2014-03-10 |
BR112012018948A2 (pt) | 2020-10-20 |
JP5923985B2 (ja) | 2016-05-25 |
US8911740B2 (en) | 2014-12-16 |
ES2583777T3 (es) | 2016-09-22 |
RU2598258C2 (ru) | 2016-09-20 |
KR101871704B1 (ko) | 2018-06-27 |
EP2532364A4 (en) | 2013-07-31 |
EP2532364B1 (en) | 2016-05-04 |
DK2532364T3 (en) | 2016-08-15 |
MX2012008997A (es) | 2012-09-07 |
US20130071398A1 (en) | 2013-03-21 |
AU2011211682A1 (en) | 2012-08-23 |
CN102834113A (zh) | 2012-12-19 |
CA2788545C (en) | 2019-03-26 |
EP2532364A1 (en) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2532364T3 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER | |
DK2532365T3 (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER | |
DK2532367T3 (en) | PHARMACEUTICAL AGENT FOR TREATMENT AND / OR CANCER PREVENTION | |
CA2788547C (en) | Pharmaceutical composition for treating and/or preventing cancer | |
CA2788718C (en) | Caprin-1 antibody for treating and/or preventing cancer | |
CA2788716C (en) | Pharmaceutical composition for treating and/or preventing cancer | |
KR102255616B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
HUE033183T2 (hu) | Rák kezelésére és/vagy megelõzésére alkalmazható gyógyszerkészítmény | |
HUE034736T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
HUE030137T2 (hu) | Rák kezelésére és/vagy megelõzésére szolgáló gyógyszerkészítmény | |
HUE035689T2 (hu) | Gyógyszerkészítmény rák kezelésére és/vagy megelõzésére |